Evaluation of Biological Activity of Different Wavelengths of Low-Level Laser Therapy on the Cancer Prostate Cell Line Compared With Cisplatin Low-Level Laser Therapy and Cancer Prostate Cell Line
Journal of Lasers in Medical Sciences,
Vol. 12 (2021),
13 Bahman 2021
,
Page e17
Abstract
Introduction: Cancer is one of the most important problems in the world. Low-level laser therapy (LLLT) has been emerged as a new approach, having both stimulation and inhibition effects on cellular function. The goal of this study was to analyze and compare the different concentrations of cisplatin and wavelengths of laser therapy on the LnCap cell lines.
Methods: LnCap cells were cultured and treated with different concentrations of cisplatin (0.1, 0.4, 0.8, 1.2 and 2 µg/mL for 24 hours) and wavelengths of laser therapy (610, 630, and 810 nm) (0.45J/cm2) separately. The viability of cells was examined by MTT assay and IC50 was also calculated. Furthermore, a combination of cisplatin IC50 (24 hours) and different wavelengths of the laser was examined.
Results: The results of this study showed that 2 µg/mL of cisplatin has the most significant reduction effect on the cell viability of the LnCap cell line. Cisplatin decreased the viability of cells in a dose-dependent manner. Moreover, IC50 of cisplatin was 1.24 µg/mL. On the other hand, LLLT with wavelengths of 610, 630, and 810 nm did not show notable biological effects on cell viability.
Conclusion: As known, cisplatin has the capability to reduce the viability of LnCap cell lines. However, LLLT cannot be a remarkable option for the treatment of prostate cancer. Therefore, although laser therapy showed praiseful therapeutic activity against some cancer cell lines, in this study the results indicated that defined laser wavelengths had no inhibitory effects against the prostate cancer cell line.
- Low level laser therapy, Prostate cancer, MTT, cell culture
How to Cite
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30. doi:10.3322/caac.21590
Erdogan B, Kostek O, Bekirhacioglu M. Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer. Eurasian j med oncol. 2018;2(3):121-9. doi: 10.14744/ejmo.2018.72098
Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. doi: org/10.3322/caac.21149
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714-26. doi: org/10.1038/nrc3599
Basu A, Krishnamurthy S. Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids. 2010; 2010:201367 doi: org/10.4061/2010/201367
Florea A-M, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers. 2011;3(1):1351-71. doi: org/10.3390/cancers3011351
Ghosh S. Cisplatin: The first metal based anticancer drug. Bioorganic chemistry. Bioorg Chem. 2019; 88:102925 doi: org/10.1016/j.bioorg.2019.102925
Farivar S, Malekshahabi T, Shiari R. Biological effects of low level laser therapy. J Lasers Med Sci. 2014;5(2):58-62. PMID: 25653800
Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ, et al. Low level laser therapy (Photobiomodulation therapy) for breast cancer-related lymphedema: a systematic review. BMC Cancer. 2017;17(1):833. doi:org/10.1186/s12885-017-3852-x
Feller JF, Greenwood BM, Stafford RJ. Transrectal Laser Focal Therapy of Prostate Cancer. In: Imaging and Focal Therapy of Early Prostate Cancer [Internet]. Springer International Publishing; 2017.p. 325–43. Available from: http://dx.doi.org/10.1007/978-3-319-49911-6_25
Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg. 2002;20(1):3-7. doi: org/10.1089/104454702753474931
Sawyers C. Targeted cancer therapy. Nature. 2004;432(7015):294-7. doi: org/10.1038/nature03095
Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532-42. doi: 10.1001/jama.2017.7248
Vale FA, Moreira MS, Almeida FCSd, Ramalho KM. Low-level laser therapy in the treatment of recurrent aphthous ulcers: a systematic review. Sci World J. 2015;2015. doi:10.1155/2015/150412
Mirza FN, Khatri KA. The use of lasers in the treatment of skin cancer: A review. J Cosmet Laser Ther. 2017 Dec;19(8):451-458. doi: 10.1080/14764172.2017.1349321.
Bown SG. New techniques in laser therapy. BMJ. 1998;316(7133):754-7. doi: org/10.1136/bmj.316.7133.754
Fried NM. Therapeutic applications of lasers in urology: an update. Expert Rev Med Devices. 2006;3(1):81-94. doi:10.1586/17434440.3.1.81
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869-83. doi:10.1038/onc.2011.384
Nematbakhsh M, Ashrafi F, Pezeshki Z, Fatahi Z, Kianpoor F, Sanei M-H, et al. A histopathological study of nephrotoxicity, hepatoxicity or testicular toxicity: Which one is the first observation as side effect of Cisplatin-induced toxicity in animal model? J Nephropathol. 2012;1(3):190. doi: 10.5812/nephropathol.8122
Huang Y-Y, Chen AC-H, Hamblin M. Low-level laser therapy: an emerging clinical paradigm. SPIE Newsroom. 2009;9:1-3. doi: 10.1117/2.1200906.1669
Gao X, Xing D. Molecular mechanisms of cell proliferation induced by low power laser irradiation. J Biomed Sci. 2009;16(1):4. doi: org/10.1186/1423-0127-16-4
Arnesano F, Losacco M, Natile G. An updated view of cisplatin transport. Eur J Inorg Chem. 2013;2013(15):2701-11. doi: org/10.1002/ejic.201300001
Kim CW, Lu JN, Go S-I, Jung JH, Yi SM, Jeong J-H, et al. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax. Int J Oncol Res. 2013;43(5):1495-502. doi: org/10.3892/ijo.2013.2070
Mansoori B, Mohammadi A, Doustvandi MA, Mohammadnejad F, Kamari F, Gjerstorff MF, et al. Photodynamic therapy for cancer: Role of natural products. Photodiagn. Photodiagn Photodyn Ther. 2019 Jun;26:395-404. DOI: 10.1016/j.pdpdt.2019.04.033.
Crescenzi E, Varriale L, Iovino M, Chiaviello A, Veneziani BM, Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol Cancer Ther. 2004;3(5):537-44.
de Freitas LM, Soares CP, Fontana CR. Synergistic effect of photodynamic therapy and cisplatin: A novel approach for cervical cancer. J Photochem. Photobiol B. 2014;140:365-73. doi: org/10.1016/j.jphotobiol.2014.08.021
- Abstract Viewed: 785 times
- PDF Downloaded: 522 times